Jazz Pharmaceuticals’ Leukemia Drug Receives European Commission Approval

Green light for the Jazz Pharmaceuticals drug in Europe. The biopharmaceutical company has received authorization from the European Commission to begin marketing Enrylaze, a basic component for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients. The European Commission’s approval extends to all EU member states, as well as Iceland, Norway and Liechtenstein.

The approval is based on the results of a phase 3 clinical trial, conducted in collaboration with the Children’s Oncology Group (COG) in a cohort of 228 pediatric and adult patients with ALL and LBL. The firm has confirmed that “the safety profile of the drug was consistent with the reported safety information for patients with ALL and LBL receiving asparaginase with combination chemotherapy.”

Robert Iannone, global head of research and development at Jazz Pharmaceuticals, said: “Healthcare professionals in the European Union will now have access to a new recombinant asparaginase derived from Erwinia with multiple dosing and administration options to address the individual needs of their patients, which will allow them to complete their treatment scheme according to the prescription ”, according to the manager.

Read more about Jazz Pharmaceuticals and find the latest financial news of the day with our companion app Born2Invest.

The EC’s approval of Jazz Pharmaceuticals’ leukemia drug extends to all EU member states, as well as Iceland, Norway, and Liechtenstein

Enrylaze is an asparaginase derived from Erwinia that was approved by the United States Food and Drug Administration (FDA) in June 2021 and began being marketed in July of that same year in the United States and Canada.

Acute lymphoblastic leukemia is a cancer of the blood and bone marrow that represents 80% of leukemia diagnoses in children, with a total incidence in Europe of 1.28 per 100,000 inhabitants. For its part, lymphoblastic lymphoma is a rare, rapidly growing, and aggressive subtype of non-Hodgkin lymphoma that is most frequently seen in adults under 35 years of age.

Jazz Pharmaceuticals is a biopharmaceutical company dedicated to the development of drugs in neuroscience and oncology. Founded in 2003 in Ireland, two years later it acquired Orphan Medical and its product, Xyrem. The Irish company has an agreement with Pharma Mar for the marketing of the drug Zepzelca on US soil. In fact, the Spanish company received 89 million euros for the approval of Zepzelca in the United States.

__

(Featured image by almathias via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.